Short hairpin rna (shRNA) ether à go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 12573-12583

  Wu, Jin ^a   Wu, Xinyu ^a   Zhong, Daixing ^b   Zhai, Wenliang ^a   Ding, Zhenqi ^a   Zhou, Yong ^b  

^a Orthopaedic Center of People s Liberation Army   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Ether ; Go go1 (Eag1); Osteosarcoma; Proliferation; Short hairpin RNA(shRNA); Vascular endothelial growth factor (VEGF)

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; ETHER A GO GO 1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; POTASSIUM CHANNEL HERG; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BONE TUMOR; GENETICS; HEK293 CELL LINE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867797052     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131012573     Document Type: Article

References (26)

1. Pardo, L.A.; Contreras-Jurado, C.; Zientkowska, M.; Alves, F.; Stuhmer, W. Role of voltage-gated potassium channels in cancer. J. Membr. Biol. 2005, 205, 115-124.
2. Camacho, J. Ether à go-go potassium channels and cancer. Cancer Lett. 2006, 233, 1-9.
3. Hemmerlein, B.; Weseloh, R.M.; de Queiroz, F.M.; Knötgen, H.; Sánchez, A.; Rubio, M.E.; Martin, S.; Schliephacke, T.; Jenke, M.; Heinz-Joachim-Radzun et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol. Cancer 2006, 5, 41.
4. + channels. EMBO J. 1999, 18, 5540-5547.
5. Asher, V.; Sowter, H.; Shaw, R.; Bali, A.; Khan, R. Eag and HERG potassium channels as novel therapeutic targets in cancer. World J. Surg. Oncol. 2010, 8, 113.
6. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
7. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29, 15-18.
8. Downie, B.R.; Sánchez, A.; Knötgen, H.; Contreras-Jurado, C.; Gymnopoulos, M.; Weber, C.; Stühmer, W.; Pardo, L.A. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J. Biol. Chem. 2008, 283, 36234-36240.
9. Rini, B.I.; Small, E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005, 23, 1028-1043.
10. Hong, T.M.; Chen, Y.L.; Wu, Y.Y.; Yuan, A.; Chao, Y.C.; Chung, Y.C.; Wu, M.H.; Yang, S.C.; Pan, S.H.; Shih, J.Y. et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin. Cancer Res. 2007, 13, 4759-4768.
11. Los, M.; Voest, E.E.; Inne H.M., Rinkes, B. VEGF as a target of therapy in gastrointestinal oncology. Dig. Surg. 2005, 22, 282-293.
12. Damron, T.A.; Ward, W.G.; Stewart, A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base report. Clin. Orthop. Relat. Res. 2007, 459, 40-47.
13. Sluga, M.; Windhager, R.; Pfeiffer, M.; Ofner, P.; Lang, S.; Dominkus, M.; Nehrer, S.; Zoubek, A.; Kotz, R. Osteosarcoma and Ewing's sarcoma-The most frequent malignant bone tumors in children-therapy and outcome. Z. Orthop. Ihre Grenzgeb. 2002, 140, 652-655.
14. Bielack, S.S.; Kempf-Bielack, B.; Delling, G.; Exner, G.U.; Flege, S.; Helmke, K.; Kotz, R.; Salzer-Kuntschik, M.; Werner, M.; Winkelmann, W. et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 2002, 20, 776-790.
15. Eppert, K.; Wunder, J.S.; Aneliunas, V.; Kandel, R.; Andrulis, I.L. von Willebrand factor expression in osteosarcoma metastasis. Mod. Pathol. 2005, 18, 388-397.
16. Murphy, P.M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 2001, 345, 833-835.
17. Kawauchi, T. Cell Adhesion and Its Endocytic Regulation in Cell Migration during Neural Development and Cancer Metastasis. Int. J. Mol. Sci. 2012, 13, 4564-4590.
18. Ko, H.M.; Seo, K.H.; Han, S.J.; Ahn, K.Y.; Choi, I.H.; Koh, G.Y.; Lee, H.K.; Ra, M.S.; Im, S.Y. Nuclear factor kappaB dependency of platelet-activating factor-induced angiogenesis. Cancer Res. 2002, 62, 1809-1814.
19. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4-25.
20. Benjamin, L.E.; Golijanin, D.; Itin, A.; Pode, D.; Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103, 159-165.
21. Klagsbrun, M.; D'Amore, P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996, 7, 259-270.
22. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669-676.
23. Stuttfeld, E.; Ballmer-Hofer, K. Structure and function of VEGF receptors. IUBMB Life 2009, 61, 915-922.
24. He, T.C.; Zhou, S.; da Costa, L.T.; Yu, J.; Kinzler, K.W.; Vogelstein, B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 1998, 95, 2509-2514.
25. Gao, Y.S.; Mei, J.; Tong, T.L.; Hu, M.; Xue, H.M.; Cai, X.S. Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice. Cancer Biother. Radiopharm. 2009, 24, 243-247.
26. García-Becerra, R.; Díaz, L.; Camacho, J.; Barrera, D.; Ordaz-Rosado, D.; Morales, A.; Ortiz, C.S.; Avila, E.; Bargallo, E.; Arrecillas, M et al. Calcitriol inhibits Ether-à go-go potassium channel expression and cell proliferation in human breast cancer. Exp. Cell Res. 2010, 316, 433-442.